In the present study, to examine and verify the fundamental strategy for treating narcoleptic symptoms including cataplexy and sleep/wake fragmentation, we compared the therapeutic efficacies of peptidic OX2R-selective and OX1R/OX2R non-selective agonists side-by-side in narcoleptic orexin knockout mice. The gene discussed is HCRT; the disease is Cataplexy.